Arthur S. Kirsch
Arthur S. Kirsch's purchase track record
Arthur S. Kirsch has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/10/2021 | LQDA | $127K | +56.7% | +16.6% | -15.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Liquidia shares fall on patent court loss and analyst downgrades. Liquidia stock is down sharply after a court ruling regarding YUTREPIA patent access, which analysts say clouds the drug's future. Wells Fargo downgraded the stock to Equal-Weight and lowered its price target to $30, while other analysts also cut their targets. The stock is currently trading near its 52-week low, reflecting significant market concern over the legal outcome.
Transaction History
| EVMN | ▲ Buy | Open Market | 10,000 | $133K | 7/7/2026 | View on chart |
| LQDA | ▲ Buy | Grant | 5,882 | $0 | 6/16/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 10,000 | $548K | 6/3/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 5,000 | $280K | 6/2/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 15,000 | $903K | 6/1/2026 | View on chart |
| LQDA | ▲ Buy | Grant | 18,396 | $0 | 6/17/2025 | View on chart |
| LQDA | ▲ Buy | Grant | 20,359 | $0 | 6/20/2024 | View on chart |
| LQDA | ▲ Buy | Open Market | 30,000 | $127K | 11/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Evommune to Present Phase 2a Data for EVO301 at EADV Congress
Evommune will present late‑breaker Phase 2a results for its atopic dermatitis drug EVO301 at the European Academy of Dermatology & Venereology Congress. The presentation follows a setback with its earlier candidate EVO756, shifting focus to the more promising EVO301. The company’s pipeline reset underscores the importance of these data for its future prospects.
Evommune to Present Phase 2a Data for EVO301 at EADV Congress. Evommune will present late‑breaker Phase 2a results for its atopic dermatitis drug EVO301 at the European Academy of Dermatology & Venereology Congress. The presentation follows a setback with its earlier candidate EVO756, shifting focus to the more promising EVO301. The company’s pipeline reset underscores the importance of these data for its future prospects.